Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. The Company’s portfolio includes five disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes. The Company’s lead clinical program, PRAX-114, is an extrasynaptic-preferring GABAA receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). The Company’s second clinical program, PRAX-944, is a potential differentiated selective small molecule inhibitor of T-type calcium channels for the treatment of Essential Tremor (ET).